NCT00370513已完成1 期
A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients With Hepatocellular Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Adverse events (AEs) and changes in vital signs and laboratory values. A dose regimen where no more than 1 out of 6 subjects experience a dose-limiting toxicity (DLT) will define the maximum tolerated dose (MTD).
研究概览
简要总结
Liver cancer is a good target for anti-angiogenic treatments such as pazopanib. The effect of pazopanib in patients with liver cancer are unknown. This study is designed to evaluate the safety, tolerability and best dose of pazopanib to be given to patient with liver cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Pazopanib Arm
Experimental
Different doses of oral pazopanib once daily for the duration of the study starting on Day 1 of Treatment Period 1. Treatment continues until disease progression or withdrawl from study.
干预措施: pazopanib (Drug)
结局指标
主要结局
Adverse events (AEs) and changes in vital signs and laboratory values. A dose regimen where no more than 1 out of 6 subjects experience a dose-limiting toxicity (DLT) will define the maximum tolerated dose (MTD).
时间窗: throughout the study
次要结局
- Various pharmacokinetic parametersAlpha-fetoprotein (AFP) measurements and scans(throughout the study)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast CancerMetastatic Breast CancerNCT01498458German Breast Group9
已完成
不适用
Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue SarcomaStage IIA Adult Soft Tissue SarcomaStage III Adult Soft Tissue SarcomaStage IV Adult Soft Tissue SarcomaNCT01446809University of Washington23
已完成
2 期
Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001Hepatocellular CarcinomaNCT00775073Gerhard Treiber33
终止
2 期
HYPAZ: Hypertension Induced by PazopanibSoft Tissue SarcomaBreast CancerOvarian CancerPancreatic CancerMelanomaCervical CancerNon-small Cell Lung CancerGlioblastomaGastrointestinal CancerRenal Cell CarcinomaSmall Cell Lung CancerNCT01392352Cambridge University Hospitals NHS Foundation Trust31
撤回
1 期
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid TumorsWilms TumorOsteosarcomaSarcomaNeuroblastomaBrain TumorNCT01130623National Cancer Institute (NCI)